FDA Approves First Treatment for Rare Menkes Disease

U.S.-based biopharmaceutical company Sentynl Therapeutics Inc, a wholly owned subsidiary of Zydus Lifesciences, has received approval from the U.S. Food and Drug Administration (FDA) for Zycubo (copper histidinate). The drug is approved for the treatment of Menkes disease in paediatric patients.

Significance of the Approval

• Zycubo is the first and only FDA-approved treatment for Menkes disease in the United States.
• The approval marks a major milestone in the management of a rare, fatal genetic disorder with no previously approved therapy.

About Menkes Disease

• Menkes disease is a rare neurodegenerative genetic disorder.
• It is caused by a defect in copper transport, which prevents the body from properly absorbing and distributing copper.
• Copper is essential for brain development and several enzymatic processes.

Clinical Features

Children affected by Menkes disease commonly show:

• Seizures
• Failure to gain weight and grow
• Developmental delays
• Intellectual disability

The disease also leads to abnormalities in:

• Vascular system
• Bladder and bowel
• Bones and muscles
• Nervous system

If untreated, Menkes disease is often fatal in early childhood.

About Zycubo (Copper Histidinate)

• Zycubo is a copper replacement therapy.
• It is administered through subcutaneous injection.
• The therapy aims to restore copper levels in the body, helping to slow disease progression when initiated early.